Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Safety Study of Atomoxetine and Cerebrovascular Outcomes
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72000
- Registration Number
- NCT00634439
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 119
- Registration Number
- NCT00628394
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Sharon Walsh
- Target Recruit Count
- 50
- Registration Number
- NCT00617201
- Locations
- 🇺🇸
Straus Research Building, Lexington, Kentucky, United States
Effects of Atomoxetine Treatment in Humans
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT00611936
Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 16
- Registration Number
- NCT00611533
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2011-12-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 209
- Registration Number
- NCT00607919
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States
Atomoxetine Effects in Humans
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2011-12-12
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT00607568
The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00566371
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00562055
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 11
- Registration Number
- NCT00548327
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.